Capstone Therapeutics Corp
Capstone Holding Corp., through its subsidiaries, engages in the distribution of masonry stone products in the United States. Its masonry stone products include manufactured and natural stone cladding products, natural stone landscape products and related goods for residential and commercial construction. The company was formerly known as Capstone Therapeutics Corp. and changed its name to Capsto… Read more
Capstone Therapeutics Corp (CAPS) - Net Assets
Latest net assets as of September 2024: $-1.92 Million USD
Based on the latest financial reports, Capstone Therapeutics Corp (CAPS) has net assets worth $-1.92 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($51.53 Million) and total liabilities ($53.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.92 Million |
| % of Total Assets | -3.73% |
| Annual Growth Rate | -17.86% |
| 5-Year Change | N/A |
| 10-Year Change | -21.46% |
| Growth Volatility | 37.19 |
Capstone Therapeutics Corp - Net Assets Trend (2005–2023)
This chart illustrates how Capstone Therapeutics Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Capstone Therapeutics Corp (2005–2023)
The table below shows the annual net assets of Capstone Therapeutics Corp from 2005 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $2.44 Million | -70.18% |
| 2022-12-31 | $8.17 Million | +30.94% |
| 2021-12-31 | $6.24 Million | +7.46% |
| 2020-12-31 | $5.81 Million | +247.34% |
| 2019-12-31 | $-3.94 Million | -216.88% |
| 2018-12-31 | $-1.24 Million | -41.52% |
| 2017-12-31 | $-879.00K | -620.49% |
| 2016-12-31 | $-122.00K | -124.11% |
| 2015-12-31 | $506.00K | -83.69% |
| 2014-12-31 | $3.10 Million | -57.00% |
| 2013-12-31 | $7.22 Million | -36.12% |
| 2012-12-31 | $11.30 Million | -22.50% |
| 2011-12-31 | $14.58 Million | -37.90% |
| 2010-12-31 | $23.47 Million | -32.41% |
| 2009-12-31 | $34.73 Million | -26.92% |
| 2008-12-31 | $47.52 Million | -20.08% |
| 2007-12-31 | $59.46 Million | -14.01% |
| 2006-12-31 | $69.15 Million | -17.86% |
| 2005-12-31 | $84.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Capstone Therapeutics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19060700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $193.04 Million | 7921.38% |
| Total Equity | $2.44 Million | 100.00% |
Capstone Therapeutics Corp Competitors by Market Cap
The table below lists competitors of Capstone Therapeutics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kodiak AI, Inc. Common Stock
NASDAQ:KDK
|
$80.03K |
|
PEAB -B-
BE:PEKB
|
$80.08K |
|
One and One Green Technologies. Inc Class A Ordinary Shares
NASDAQ:YDDL
|
$80.20K |
|
Abeo SA
STU:4A8
|
$80.22K |
|
AmorePacific Group Inc. Pfd. Series 1
KQ:002795
|
$79.99K |
|
BCP Investment Corp.
NASDAQ:BCIC
|
$79.97K |
|
VIA optronics AG
PINK:VIAOY
|
$79.96K |
|
Southern Financial Corporation
PINK:SFCO
|
$79.92K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Capstone Therapeutics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 8,172,000 to 2,437,000, a change of -5,735,000 (-70.2%).
- Net loss of 3,819,000 reduced equity.
- Share repurchases of 389,000 reduced equity.
- Other factors decreased equity by 1,527,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.82 Million | -156.71% |
| Share Repurchases | $389.00K | -15.96% |
| Other Changes | $-1.53 Million | -62.66% |
| Total Change | $- | -70.18% |
Book Value vs Market Value Analysis
This analysis compares Capstone Therapeutics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.12x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-16.16 | $1.92 | x |
| 2018-12-31 | $-22.87 | $1.92 | x |
| 2019-12-31 | $-60.71 | $1.92 | x |
| 2020-12-31 | $73.26 | $1.92 | x |
| 2021-12-31 | $78.72 | $1.92 | x |
| 2022-12-31 | $51.85 | $1.92 | x |
| 2023-12-31 | $15.46 | $1.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Capstone Therapeutics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -156.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.90%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 21.63x
- Recent ROE (-156.71%) is below the historical average (-41.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 11.63% | 13.88% | 0.76x | 1.11x | $784.70K |
| 2003 | 58.43% | 0.00% | 0.00x | 1.05x | $60.04 Million |
| 2014 | -134.29% | 0.00% | 0.00x | 1.09x | $-4.48 Million |
| 2015 | -547.63% | 0.00% | 0.00x | 3.49x | $-2.82 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-650.80K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.67 Million |
| 2018 | 0.00% | -19.00% | 1.35x | 0.00x | $-255.60K |
| 2019 | 0.00% | -14.84% | 49.19x | 0.00x | $-1.74 Million |
| 2020 | 180.01% | 23.00% | 0.83x | 9.45x | $9.87 Million |
| 2021 | 62.83% | 5.87% | 1.10x | 9.75x | $3.30 Million |
| 2022 | 28.33% | 3.76% | 0.94x | 7.98x | $1.50 Million |
| 2023 | -156.71% | -7.90% | 0.92x | 21.63x | $-4.06 Million |
Industry Comparison
This section compares Capstone Therapeutics Corp's net assets metrics with peer companies in the Building Materials industry.
Industry Context
- Industry: Building Materials
- Average net assets among peers: $87,759,505,135
- Average return on equity (ROE) among peers: -1005.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Capstone Therapeutics Corp (CAPS) | $-1.92 Million | 11.63% | N/A | $80.00K |
| Anhui Conch Cement Co Ltd (AHCHY) | $6.85 Billion | 5.94% | 1.81x | $19.28 Billion |
| Amrize Ltd (AMRZ) | $8.21 Billion | 13.50% | 1.52x | $27.46 Billion |
| Basanite Inc (BASA) | $181.76K | -9065.80% | 27.67x | $7.57 Million |
| PT Berkah Beton Sadaya Tbk (BHBSY) | $771.79 Billion | 15.93% | 0.06x | $360.00 Million |
| BRDNF (BRDNF) | $1.11 Billion | 9.50% | 0.69x | $1.54 Billion |
| Brickworks Limited (BRKWF) | $1.84 Billion | 4.25% | 0.37x | $1.23 Billion |
| Capstone Holding Corp. Common Stock (CAPS) | $-879.00K | 0.00% | 0.00x | $3.74 Million |
| Captivision Inc. (CAPT) | $-12.26 Million | 0.00% | 0.00x | $11.82 Million |
| China GengSheng Minerals Inc (CHGS) | $40.48 Million | -33.45% | 3.01x | $0.97 |